Previous 10 | Next 10 |
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial...
Atea Pharmaceuticals (NASDAQ: AVIR) recently reported phase 2 results for its oral SARS-CoV-2 treatment, AT-527, and the data look promising: AT-527 may offer a convenient, effective treatment to prevent disease progression both in and out of the hospital. If Atea is able to earn re...
BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D...
Morsa Images/DigitalVision via Getty Images Atea Pharmaceuticals ([[AVIR]] -5.1%) and Roche's ([[RHHBY]] -0.2%) oral anti-viral drug for COVID-19, AT-527, reduced viral loads in hospitalized patients, according to interim phase 2 data. Virology analysis showed that at day 2, patients who rece...
Ocuphire Pharma (OCUP) +71% after Phase 2 VEGA-1 trial in presbyopia meets endpoints.Vertex Energy (VTNR) +43% as Clean Harbors to acquire certain assets.Verb Technology Company (VERB) +37%.Bridgeline Digital (BLIN) +29%.AST SpaceMobile (ASTS) +22%.Exela Technologies (XELA) +2...
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting AT-527 is Being Studied in Multiple Clinical Studies, Including Global Phase 2 MOONSONG and Phase 3 MORNINGSKY Trials, with Res...
sittithat tangwitthayaphum/iStock via Getty Images The Biden administration says it will invest more than $3B to develop the next-generation of drugs to treat COVID-19. The Antiviral Program for Pandemics aims to develop oral antivirals that can be taken at home in the early stages of in...
loops7/E+ via Getty Images Atea Pharmaceuticals ([[AVIR]] +4.9%) is on the rise on the news of a potential deal with the government for AT-527, the company’s experimental oral antiviral against COVID-19. The U.S. government is set to invest $3.2B for the development of antiviral pills ...
BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it has achieved a milestone ...
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice Preside...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...